APA (7th ed.) Citation

C, I., D, R., C, D., M, N., L, P., G, R., . . . S, S. (2022). In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies. Journal for immunotherapy of cancer, 10(3), . https://doi.org/10.1136/jitc-2021-004032

Chicago Style (17th ed.) Citation

C, Ieranò, et al. "In PD-1+ Human Colon Cancer Cells NIVOLUMAB Promotes Survival and Could Protect Tumor Cells from Conventional Therapies." Journal for Immunotherapy of Cancer 10, no. 3 (2022). https://doi.org/10.1136/jitc-2021-004032.

MLA (9th ed.) Citation

C, Ieranò, et al. "In PD-1+ Human Colon Cancer Cells NIVOLUMAB Promotes Survival and Could Protect Tumor Cells from Conventional Therapies." Journal for Immunotherapy of Cancer, vol. 10, no. 3, 2022, https://doi.org/10.1136/jitc-2021-004032.